QDENGA Dengue Vaccine to Hit India Market in 2027; Dr Reddy’s to Sell It
The vaccine, approved for ages 4 to 60, will be sold in India’s private market after regulatory steps are completed.
- On Friday, Dr. Reddy's Laboratories and Takeda Pharmaceutical signed an agreement to promote and distribute the Qdenga dengue vaccine across India's private market for paediatric and adult vaccination.
- Dengue cases in India have surged 11-fold over 20 years, with the World Health Organization reporting 232,425 cases and 233 deaths in 2024, creating urgent prevention needs.
- Qdenga, or TAK-003, is a live-attenuated vaccine approved for people aged 4 to 60 years, administered in two 0.5 ml doses three months apart to protect against all four dengue serotypes.
- Subject to final regulatory processes, the vaccine is expected to become available in India in the first half of 2027, with Dr. Reddy's and Takeda collaborating on healthcare-professional engagement and dengue awareness.
- Takeda retains public-market rights and welcomed the Parliamentary Committee on Health's recommendation to include Qdenga in the Universal Immunization Program, reflecting growing recognition of dengue as a public-health priority.
25 Articles
25 Articles
The first dengue vaccine in India may be available in the first six months of 2027, with the QDENGA vaccine from Japanese company Takeda having received marketing authorisation from the CDSCO.
India's first dengue vaccine to arrive in 2027: What is Qdenga and how does it work?
Dr Reddy's Laboratories has signed with Takeda to promote and distribute the Qdenga dengue vaccine in India, with availability expected in the first half of 2027 after regulatory and market authorisation processes. The development offers another potential prevention option as dengue remains a public health concern, while mosquito control measures continue to be important.
Takeda and Dr. Reddy’s Laboratories Enter into Exclusive Collaboration to Promote and Distribute QDENGA® in India’s Pediatric and Adult Private Market
Get latest articles and stories on India at LatestLY. Takeda Pharmaceutical Company Limited, through its Indian subsidiary Takeda Biopharmaceuticals India Private Limited (together referred to as “Takeda”) and Dr Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr Reddy’s”) today entered into a distribution agreement under which Dr Reddy’s will promote and dis…
Coverage Details
Bias Distribution
- 54% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
